Endometriosis-associated ovarian carcinoma: Differential expression of vascular endothelial growth factor and estrogen/progesterone receptors

Cancer

Volumn 98, Issue 8, 2003, Pages 1658-1663

  Del Carmen, Marcela G ^a,e   Sehdev, Anne E Smith ^a   Fader, Amanda Nickles ^b   Zahurak, Marianna L ^c   Richardson, Michael ^d   Fruehauf, John P ^d   Montz, F J ^a   Bristow, Robert E ^a  

^a JOHNS HOPKINS HOSPITAL   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c JOHNS HOPKINS UNIVERSITY   (United States)

^d Oncotech Inc   (United States)

^e Gillette Center for Women's Cancers   (United States)

Author keywords

Endometriosis; Estrogen receptor; Ovarian carcinoma; Progesterone receptor; Vascular endothelial growth factor

Indexed keywords

BIOCHEMICAL MARKER; CYTOKINE; ESTROGEN RECEPTOR; GROWTH FACTOR; KI 67 ANTIGEN; PROGESTERONE RECEPTOR; VASCULOTROPIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DISEASE ASSOCIATION; EARLY DIAGNOSIS; ENDOMETRIOSIS; EPITHELIUM CELL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOHISTOCHEMISTRY; MALIGNANT TRANSFORMATION; OVARY CARCINOMA; PREMENOPAUSE; PRIORITY JOURNAL; PROTEIN EXPRESSION; SAMPLING; STAINING;

ENDOMETRIOSIS; ENDOTHELIAL GROWTH FACTORS; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; KI-67 ANTIGEN; LYMPHOKINES; OVARIAN NEOPLASMS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 0141889276     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.11714     Document Type: Article

References (36)

1. Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancer J Clin. 2001;51:15-36.
2. Stenchever MA, Droegemueller W, Herbst AL, Mishell DR. Comprehensive gynecology (4th edition). St Louis: Mosby, 2001.
3. Swiersz LM. Role of endometriosis in cancer and tumor development. Ann N Y Acad Sci. 2002;955:281-292.
4. Sampson J. Endometrial carcinoma of the ovary, arising in endometrial tissue in that organ. Arch Surg. 1925;10:1-72.
5. Seidman JD. Prognostic importance of hyperplasia and atypia in endometriosis. Int J Gynecol Pathol. 1999;15:1-9.
6. Mostoufizadeh M, Scully RE. Malignant tumors arising in endometriosis. Clin Obstet Gynecol. 1980;23:951-963.
7. Vercellini P, Parazzini F, Bolis G, et al. Endometriosis and ovarian cancer. Am J Obstet Gynecol. 1993;169:181-182.
8. Brinton L, Gridley M, Persson I, Baron J, Berqvist A. Cancer risk after a hospital discharge diagnosis if endometriosis. Am J Obstet Gynecol. 1997;176:572-579.
9. Fukunaga M, Nomura K, Ishikawa E, Ushigome S. Ovarian atypical endometriosis: its close association with malignant epithelial tumours. Histopathology. 1997;30:249-255.
10. Ogawa S, Kau T, Amada S, et al. Ovarian endometriosis associated with ovarian carcinoma: a clinicopathological and immunohistochemical study. Gynecol Oncol. 2000;77:298-304.
11. Brustmann H, Naude S. Vascular endothelial growth factor expression in serous ovarian carcinoma: relationship with high mitotic activity and high FIGO stage. Gynecol Oncol. 2002;84:47-52.
12. Boocock CA, Charnock-Jones DS, Sharkey AM, et al. Expression of vascular endothelial growth factor and its receptors flt and KDR in ovarian carcinoma. J Natl Cancer Inst. 1995; 87:506-516.
13. Fujishita A, Nakane PK, Koji T, Masuzaki H. Expression of estrogen and progesterone receptors in endometrium and peritoneal endometriosis: an immunohistochemical and in situ hybridization study. Fertil Steril. 1997;67:856-864.
14. Nisolle M, Casanas-Roux F, Donnez J. Immunohistochemical analysis of proliferative activity and steroid receptor expression in peritoneal and ovarian endometriosis. Fertil Steril. 1997;68:912-919.
15. Olson TA, Mohanraj D, Ramakrsihnan S. In vivo neutralization of vascular endothelial growth factor (VEGF)/vascular permeability factor (VPF) inhibits ovarian carcinoma-associated ascites formation and tumor growth. Int J Oncol. 1996;8:505-511.
16. Mu J, Abe Y, Tsutsui T, et al. Inhibition of growth and metastasis of ovarian carcinoma by administering a drug capable of interfering with vascular endothelial growth factor activity. Jpn J Cancer Res. 1996;87:963-971.
17. Grant SW, Kyshtoobayeva A, Kurosaki T, Jacowatz J, Fruehauf JP. Mutant p53 correlates with reduced expression of thrombospondin-1, increased angiogenesis and metastatic progression in melanoma. Cancer Detect Prev. 1998;22:185-194.
18. Poller DN, Roberts EC, Bell JA, Elston CW, Blamey RW, Ellis IO. p53 protein expression in mammary ductal carcinoma in situ: relationship to immunohistochemical expression of estrogen receptor and c-erb-B-2 protein. Hum PathoL 1993;24:463-468.
19. Cox DR. The analysis of binary data. London: Methuen, 1970.
20. Cytel Software Corporation. LogXact user's manual. Cambridge, MA: Cytel, 1992.
21. SAS Institute. SAS user's guide: statistics (Version 5 edition). Cary, NC: SAS Institute, 1985.
22. Erze M, Rakar S, Klancar B, Syrjanen K. Endometriosis-associated ovarian carcinoma (EAOC): an entity distinct from other ovarian carcinomas as suggested by a nested case-control study. Gynecol Oncol. 2001;83:100-108.
23. McMeekin DS, Burger RA, Manetta A. Endometrioid adenocarcinoma of the ovary and its relationship to endometriosis. Gynecol Oncol. 1995;59:81-86.
24. Chalas E, Chumas J, Barbieri R, Mann WJ. Nuclear organizer regions in endometriosis, atypical endometriosis, and clear cell and endometrioid carcinomas. Gynecol Oncol. 1991;40: 260-263.
25. Ballouck F, Ross JS, Wolf BC. Ovarian endometriotic cysts: an analysis of cytologic atypia and DNA ploidy patterns. Am J Clin Pathol. 1994;102:415-419.
26. Shen GH, Ghazizadeh M, Kawamani O, et al. Prognostic significance of vascular endothelial growth factor expression in human ovarian carcinoma. Br J Cancer. 2000;83:196-203.
27. Hu YL, Tee MK, Goetzl EJ, et al. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells. J Natl Cancer Inst. 2001;93:762-768.
28. Mesiano S, Ferrara N, Jaffe RB. Role of vascular endothelial growth factor in ovarian cancer: inhibition of ascites formation by immunoneutralization. Am J Pathol. 1998;153:1249-1256.
29. Folkman J. A new link in ovarian cancer angiogenesis: lysophosphatidic acid and vascular endothelial growth factor expression. J Natl Cancer Inst. 2001;93:734-735.
30. Deguchi M, Matsumoto Y, Ishiko O, Ogita S. Angiogenesis in ovarian clear cell carcinoma and its relation to endometriosis. Oncol Rep. 2000;7:651-654.
31. Gerdes J, Schwab U, Lemke H, Stein H. Production of a mouse monoclonal antibody reactive with a human nuclear antigen associated with cell proliferation. Int J Cancer. 1983;31:13-20.
32. Silvestri F, Bussani R, Pavletic N, Mannone T, Bosatra A. From epithelial dysplasia to squamous carcinoma of the head and neck region: evolutive and prognostic histopathological markers. Acta Otolaryngol Suppl. 1997;527:49-51.
33. Ioachim E, Assimakopoulos D, Agnantis NJ, Peschos D, Zissi A, Skevas A. Altered patterns of retinoblastoma gene product expression in benign, premalignant and malignant epithelium of the larynx: an immunohistochemical study including correlation with p53, bcl-2, and proliferating indices. Anticancer Res. 1999;19:541-545.
34. Shen KL, Harn HJ, Ho LI, Yu CP, Chiu SC, Lee WH. The extent of proliferative and apoptotic activity in intraductal and invasive ductal breast carcinomas detected by Ki-67 labeling and terminal deoxynucleotidyl transferase-mediated digoxigenin-11-dUTP nick end labeling. Cancer. 1998; 82:2373-2381.
35. Payne S, Kernohan NM, Walker F. Proliferation in the normal cervix and in preinvasive cervical lesions. J Clin Pathol. 1996;49:667-671.
36. Bulten J, van der Laak JA, Gemmink JH, Pahlplatz NM, de Wilde PC, Hanselaar AG. MIB1, a promising marker for the classification of cervical intraepithelial neoplasia. J Pathol. 1996;178:268-273.